LDL-C
Understanding LDL-C
Note: While VLDL, IDL, LDL, or Lp(a) particles in themselves are not "bad", high levels of these lipoproteins can build up and block arteries (pro-atherogenic). These lipoproteins, however, are healthy in moderation, and very low levels can have negative implications, too.
Why does SiPhox measure LDL-C if ApoB is better at identifying risk of atherosclerosis?
Despite advancements in understanding atherosclerosis risks, LDL-C continues to hold value in cardiovascular risk assessment and is included as a biomarker in SiPhox Health panels. This persistence is due in part to the extensive body of guidelines and recommendations that still prioritize LDL-C levels. Measuring LDL-P poses its own challenges due to difficulties in achieving precise measurements. To bridge this gap, SiPhox also includes ApoB in its assessments, offering a broader view of atherogenic particles, encompassing LDL-P. This dual measurement strategy ensures that both healthcare providers and patients have a comprehensive understanding of atherosclerotic cardiovascular disease risk, facilitating more informed health decisions (Cole, 2023).
How can I better understand my results?
To better interpret your results, Johns Hopkins Medicine has released ranges for LDL-C:
- Optimal: < 100 mg/dL
- Elevated: 100-130 mg/dL
- Borderline High: 130-160 mg/dL
- High: 160-190 mg/dL
- Very High: > 190 mg/dL
If your LDL-C is elevated, here are some lifestyle changes you can try:
- Avoiding foods with saturated fat, trans fat, and cholesterol
- Maintaining a healthy weight
- Regularly exercising
- Quitting cigarettes
- Increasing soluble fiber intake
- Supplementing with whey protein
- Limiting alcohol intake
Where can I learn more?
CDC - LDL and HDL Cholesterol and Triglycerides
Peter Attia, M.D. - Intro to lipids & lipoproteins: why there is no ‘bad’ or ‘good’ cholesterol (video)
Scientific literature:
Cole J, Zubirán R, Wolska A, Jialal I, Remaley AT. Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change? J Clin Med. 2023 Sep 3;12(17):5737. doi: 10.3390/jcm12175737. PMID: 37685804; PMCID: PMC10488498.
Duncan MS, Vasan RS, Xanthakis V. Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years. J Am Heart Assoc. 2019 Jun 4;8(11):e011433. doi: 10.1161/JAHA.118.011433. Epub 2019 May 29. PMID: 31137992; PMCID: PMC6585376.
Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011 Mar-Apr;5(2):105-13. doi: 10.1016/j.jacl.2011.02.001. PMID: 21392724; PMCID: PMC3070150.
DISCLAIMER: IF YOU ARE CONCERNED WITH ANY OF YOUR RESULTS, PLEASE CONSULT WITH YOUR PHYSICIAN.